Antitumor Activity of Lenvatinib (E7080): An Angiogenesis Inhibitor That Targets Multiple Receptor Tyrosine Kinases in Preclinical Human Thyroid Cancer Models
Figure 1
Antitumor activity of lenvatinib in human thyroid cancer xenograft models in nude mice. Nude mice bearing tumor xenografts were treated orally once daily with either vehicle or lenvatinib at the indicated doses when tumor volumes reached between 100 and 300 mm3 (day 1). Each group consisted of 5 mice. The change in tumor volume in the treated group relative to that in the control group (%) was calculated as , where and are the change in tumor volume for the treated and vehicle control group, respectively. (a) DTC xenograft models. on day 15. (b) ATC xenograft models. on day 15. (c) TT xenograft model. on day 29. Data are shown as means ± SD. compared with vehicle-treated mice.
